Potts Jeannette sold $145K of QURE

Potts Jeannette (Chief Legal Officer) sold 5,237 shares of uniQure N.V. (QURE) at $27.67 ($0.14M total) on 2026-06-15.

Original reporting
SEC EDGAR · Potts Jeannette
Published Jun 17, 2026, 8:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Neutral
medium confidence
Mentioned
$QURE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

This adds incremental transparency on insider activity but does not include operational, clinical, regulatory, or financial performance changes.

02

Market read

Traders may monitor for follow-on insider selling, but the disclosed transaction size and lack of accompanying fundamental catalysts suggest limited immediate trading impact.

03

What to watch

Insider sales can be driven by taxes, diversification, or pre-existing personal liquidity needs; the filing provides no rationale or forward guidance.

Relevance 4/10Novelty 5/10Timing: filed 2026-06-17 (covers sale dated 2026-06-15)

Background

The article is an SEC Form 4 insider transaction disclosure for uniQure N.V., reporting an officer’s open-market sale.

Company-level read

Ticker impact

$QURENeutralMedium confidence
Context

uniQure N.V. (QURE) disclosed an officer open-market sale: 5,237 shares sold on 2026-06-15 at $27.6700 for ~$144.9K.

Expected impact

Likely limited near-term impact; any reaction should be muted unless follow-on selling accelerates.

Evidence & confidence

Form 4 insider transactions are common and this one is modest in dollar value; absence of a 10b5-1 plan can raise attention but the disclosure alone rarely drives sustained repricing.

Market effects

No sector read-across; this is company-specific insider liquidity/portfolio activity.

None indicated.

None indicated.

Counterpoint

The lack of a pre-arranged 10b5-1 plan could be interpreted as less “scheduled” selling, potentially signaling management discretion rather than a planned cadence.

Key entities

  • uniQure N.V.

    Subject of the Form 4 insider sale disclosure.

  • Potts Jeannette

    Chief Legal Officer who sold 5,237 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREMedAI 8/10

QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?

uniQure N.V. (QURE) shares rose 17.5% in a month, outperforming the industry and S&P 500. The rally was driven by FDA acceptance of its Huntington's disease drug application, ifezuntirgene inilparvovec, for review. Despite weaker Q3 2026 results, investors focus on the drug's potential. QURE's cash position is strong, with $768.4M as of Sept. 30, 2026, expected to fund operations through 2030.

$QUREMedAI 8/10

uniQure Prepares for Potential FDA Panel on Huntington’s Gene Therapy After Priority Review Nod

uniQure (QURE) is preparing for a potential FDA panel review of its gene therapy AMT-130 for Huntington's disease after receiving a priority review nod. The company presented 48-month data showing treated patients had less functional decline than untreated ones, though control group limitations were noted. uniQure plans a confirmatory study and is preparing for a potential launch, with $780 million in cash to fund operations into 2030.

$QUREHighAI 9/10

Key facts: AMT-130 Priority Review; 48-Month Data; Q3 Revenue +40%

uniQure's AMT-130 was accepted for FDA Priority Review with a decision goal of May 1, 2027. The U.K. validated its marketing application. 48-month data showed slowed Huntington’s disease progression. Q3 2026 revenue rose 40.4% to $5.2 million, below estimates, with net loss narrowing to $61.2 million. Cash reserves were $768.4 million.

MedAI 8/10

uniQure N.V. Q3 2026 Earnings Call Summary

uniQure N.V. reported that the FDA accepted its AMT-130 BLA with priority review for Huntington's disease, citing 36-month data showing a 60% slowing in TFC decline. The company plans a focused commercial launch targeting 15-30 priority institutions. Management expects the confirmatory study to be underway by the 2027 PDUFA date and cash runway to extend into 2030. SG&A expenses increased by $4.5 million year-over-year.

$QUREMed

uniQure (QURE) Q3 2026 Earnings Call Transcript

uniQure (QURE) reported progress in its Q3 2026 earnings call. The company's AMT-130 therapy for Huntington's disease showed a 75% slowing of disease progression in trials. The FDA is reviewing the Biologics License Application (BLA) with a PDUFA date of May 1, 2027. uniQure is preparing for a potential U.S. launch in 2027 and advancing its pipeline, including studies for AMT-260 and AMT-191. The company is also building its commercial teams ahead of the planned launch.